Observation and evaluation of the therapeutic effect of high voltage and long duration pulsed radiofrequency on lumbar sympathetic ganglia in diabetic neuralgia

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300075470

Enrollment

Unknown

Registered

2023-09-06

Start date

2022-07-08

Completion date

Unknown

Last updated

2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic neuralgia

Interventions

C group:Drug conservative treatment

S group:Standard pulse radiation frequency of Lumbar sympathetic

H group:High voltage and long-time pulse radio frequency of Lumbar sympathetic

Eligibility

Sex/Gender

All

Age

40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) The patients sign the informed consent for this experiment. 2). Diabetic neuralgia patients over the age of 40, male or female. 3) Hospitalized patients with pain intensity VAS = 5 points. 4) The patients can follow the medication dosage and visit plan. 5) The patients can objectively describe symptoms, can actively cooperate, without any mental illness

Exclusion criteria

Exclusion criteria: 1) The patients do not meet the inclusion criteria. 2) The general condition is weak, cannot objectively describe the symptoms, or have serious infection, respiratory insufficiency cannot actively cooperate. 3) Patients who suffer from allergic diseases and are allergic; Have a history of drug sensitivity with similar drug structure (pregabalin, tramadol); 4) Epilepsy patients and family history of epilepsy; 5). Severe systemic infection or HIV infection; 6) There are contraindications for nerve puncture surgery. 7) Patients with contraindications related to experimental drugs such as severe peptic ulcer, pancreatitis, intestinal obstruction and asthma; 8). Patients suspected or with a history of drug abuse; 9) Patients who have participated in drug trials (including the drug in the test) within 3 months before the test; 10). The researcher believes that there is any reason not to be accepted

Design outcomes

Primary

Measure	Time frame
Visual analogue scale;Blood flow map of the lesion area by laser speckle flow imager;Resting fMRI scans;	—

Secondary

Measure	Time frame
Pittsburgh Sleep Quality Index;SF-36 Quality of life ;	—

Countries

China

Contacts

Public ContactHuang Xiang

The First People's Hospital of Foshan

leohuangxiang@163.com+86 180 3886 2234

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026